Fact CheckerSign in

NCT07755917Not yet recruiting

Preoperative Home-based Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health

Preoperative Multi-mode Prehabilitation Management for Neoadjuvant Chemotherapy Gastric Cancer Patients Supervised at Home Based on 5G + AI Mobile Health (mHealth): A Multicenter RCT

Source: ClinicalTrials.gov · Last updated 10 Aug 2026

Brief summary (registry, in English)

The goal of this prospective, multicenter, open-label randomized controlled clinical trial is to evaluate whether a home-based, digitally supervised multi-modal prehabilitation intervention can improve functional capacity, treatment tolerance, and short- and long-term clinical outcomes in gastric cancer patients who have completed 2-4 cycles of neoadjuvant chemotherapy and are scheduled for radical gastrectomy.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
490 (estimated)
First submitted
2 Aug 2026
Start date
31 Aug 2026
Primary completion date
1 Sept 2028
Lead sponsor
The Affiliated Hospital of Qingdao University
NCT number
NCT07755917

What you commit to

  • Study type: Interventional
  • Planned participants: 490
  • From 31 Aug 2026 to the primary completion date, 1 Sept 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Within 6 months before enrollment, the patient had experienced cerebral hemorrhage, cerebral infarction, TIA, or suffered from central nervous system diseases or mental disorders, and was unable to cooperate in completing neoadjuvant therapy and prehabilitation

Other illness

  • Presence of severe systemic infections (e.g., multiple organ dysfunction syndrome \[MODS\]) or active infectious diseases (e.g., tuberculosis)
  • Emergency surgery is required due to complications of the tumor (e.g. bleeding, perforation, obstruction)
  • Simultaneous tumors or other diseases requiring simultaneous surgery (excluding laparoscopic cholecystectomy)

Lab values

  • Severe cardiac dysfunction (preoperative LVEF \< 30% or NYHA classification IV), severe liver dysfunction (Child-Pugh C grade), severe kidney dysfunction (preoperative CRRT was received), ASA grade IV or above; 6MWD ≤ 250 meters

Other

  • Distant metastasis
  • Patients who are participating in any other clinical trials (except observational, non-interventional clinical study)

Who the study is looking for

  • Aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Histologically confirmation of gastric or gastroesophageal junction (GEJ) adenocarcinoma. For GEJ carcinomas, eligibility is strictly confined to those presenting with Siewert type III tumors or Siewert type II tumors that do not mandate a concurrent thoracotomy
  • Surgery is planned after neoadjuvant therapy
  • Capacity to comprehend and voluntarily sign a written informed consent form
  • Ability to use digital technology (e.g., smart phones, wearable devices) independently or with the assistance of family members

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.